Independent
Tenure on this board
1.7 yrs
2 nominees · 2 ballot items.
Election of two Class II directors (Christopher Bowden, M.D. and Carolyn Ng, Ph.D.) and ratification of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Elect two Class II directors to the board to serve three-year terms expiring in 2029 (nominees: Christopher Bowden, M.D. and Carolyn Ng, Ph.D.).
Ratify the audit committee’s appointment of KPMG LLP as Bicara Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 11.04% | 7,255,993 | $144M |
| 2 | T. Rowe Price Investment Management, Inc. | 10.05% | 6,605,780 | $131M |
| 3 | Siren, L.L.C. | 8.83% | 5,802,970 | $115M |
| 4 | Vestal Point Capital, LP | 8.26% | 5,425,000 | $108M |
| 5 | Deep Track Capital, LP | 6.18% | 4,062,500 | $81M |
| 6 | JANUS HENDERSON GROUP PLC | 5.06% | 3,326,918 | $66M |
| 7 | Red Tree Management, LLC | 4.83% | 3,170,509 | $63M |
| 8 | TPG GP A, LLC | 4.58% | 3,010,425 | $60M |
| 9 | Omega Fund Management, LLC | 3.64% | 2,392,150 | $48M |
| 10 | Royalty Pharma Sub-Manager, LLC | 3.63% | 2,388,150 | $47M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.